Akebia Gets FibroGen Anemia Drug Patents Invalidated In UK

By Bonnie Eslinger ( April 20, 2020, 9:14 PM BST) -- A London judge on Monday invalidated five patents covering FibroGen Inc. 's anemia treatments and found that Akebia Therapeutics Inc. did not infringe its competitor's sixth patent, ruling that most of the patents were either obvious or insufficiently detailed. . . .

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Law360 is pleased to announce the Rising Stars of 2025, our list of more than 150 attorneys under 40 whose legal accomplishments belie their age.